Phase 3
N=17
Efficacy of SLN Block for Chronic Cough
Cough · Superior Laryngeal Nerve Block · Neurogenic Cough
Bottom Line
View on ClinicalTrials.gov: NCT04421092 ↗Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Change in Cough Severity — 13.15; 9.54 LCQ scores (baseline to 3 months)
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Superior laryngeal nerve block (Procedure); Injection of placebo (saline) (Procedure); Injection of steroid-lidocaine mixture (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Medical University of South Carolina
- Primary completion
- Dec 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Cough Severity |
13.15; 9.54 | — |
| SECONDARY Subjective Improvement in Cough |
10; 7 | — |
| SECONDARY Summed Daily Change in Subjective Cough Severity |
13.15; 9.54 | — |
Summary
This is a research study to find out if superior laryngeal nerve blocks are an effective way to reduce cough when compared to placebo (a substance without any medical value). Eligibility for the study include the following: age >18, cough history suggestive that the nerve to the voice box is overactive, non-smoker, Patients will be followed over time and assigned to either the treatment or placebo group at random. The treatment would be four superior laryngeal nerve blocks and the placebo would be four saline injections (the inactive substance). Study team will measure if the injection improved cough and ask patients to keep a log of symptoms and fill out questionnaires at each visit. After the four injections, patients will follow up in 3 months to see if cough has returned and if so, how severe the cough is.
Eligibility Criteria
Inclusion Criteria
- History consistent with neurogenic cough
- Exclusion of other etiologies (see exclusion criteria)
- Age ≥ 18
Exclusion Criteria
- Current neuromodulating medication use
- Untreated other etiologies of cough:
Current smoker Current ACE/ARB use Abnormal PFTs within 6 months Uncontrolled OSA Abnormal CXR within 6 months RSI > 13 or RFS >11 AND workup positive for GERD (esophagram, 24-hour pH probe, manometry, EGD)
Data sourced from ClinicalTrials.gov (NCT04421092). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.